Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Dr. Makarand Jawadekar, Ph.D

Dr. Makarand Jawadekar, Ph.D

Independent Pharma Professional

Connect with Dr. Makarand Jawadekar, Ph.D on LinkedIn
Website:

About the author: Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at Pfizer Inc. based in Groton-New London Connecticut for 28 consecutive years. He worked as a Director, Portfolio Management. During his career at Pfizer, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota..Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011.

Posts by Dr. Makarand Jawadekar, Ph.D

FDA Regulations Reform? Risks and Benefit for the Approval Process of New Drugs

Posted on June 2nd, 2017 in Pharma R&D

Know the rules

Since 1906, the US Food and Drug Administration (FDA) through regulations has been responsible for ensuring the approval of new drugs whose health benefits outweigh the known risks associated with the drug.

(more…)

Emerging Oncology Drugs in Pharma R&D Pipeline

Posted on March 2nd, 2017 in Pharma R&D

Cancer. It’s the 2nd leading cause of death in this country (1), and a disease feared by patients and healthcare professionals alike. Today’s cancer treatments vary in nature, and also, efficacy and levels of side effect profiles. (more…)

Mergers and Acquisitions in the Pharma Industry

Posted on February 8th, 2017 in Pharma R&D

It seems we cannot go a month without seeing in the news another acquisition by a big pharmaceutical company. (more…)

2016 US Elections Fearful or Fertile Ground for Pharma?

Posted on November 10th, 2016 in Pharma R&D

The elections outcome, the morning after, which is so fresh in everyone’s mind that we need to see how a Trump Presidency will shape the future growth of the US economy and in turn ultimately allow growth in innovation in Pharma Industry. (more…)

  1. 1
  2. 2
  3. 3
  4. 4